Ligand id: 8957

Name: cerdulatinib

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 10
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 141.93
Molecular weight 445.19
XLogP 1.19
No. Lipinski's rules broken 0

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Cerdulatinib is being evaluated in Phase I clinical trial for its potential to treat chronic lymphocytic leukaemia (CLL) and lymphomas (small lymphocytic lymphoma, SLL and non-Hodgkin lymphoma, NHL)- see clinical trial NCT01994382.
Mechanism Of Action and Pharmacodynamic Effects
Cerdulatinib is a reversible ATP-competitive small molecule kinase inhibitor. SYK and JAK independently contribute to the pathogenesis of certain autoimmune and malignant disorders, therefore simultaneous inhibition of both pathways is expected to deliver improved disease therapy in comparision to selective kinase inhibition.